Last reviewed · How we verify
Glucosylceramide beta-glucosidase deficiency
Approved treatments
- Cerezyme · Sanofi
Cerezyme replaces the deficient enzyme in patients with Gaucher disease, allowing for the breakdown of glucocerebroside. - Cerdelga · Sanofi
Cerdelga works by inhibiting the enzyme ceramide glucosyltransferase, which is involved in the production of glucosylceramide. - Glustat
- Zavesca · AstraZeneca
Zavesca works by inhibiting the enzyme glucosylceramide synthase, which is involved in the production of a toxic lipid that accumulates in cells of patients with certain lysosomal storage disorders.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Glucosylceramide beta-glucosidase deficiency patent landscape — cliff calendar, originator estates, attackable patents
- Glucosylceramide beta-glucosidase deficiency treatment landscape brief
- Glucosylceramide beta-glucosidase deficiency treatment updates RSS
Frequently asked questions about Glucosylceramide beta-glucosidase deficiency
What drugs treat Glucosylceramide beta-glucosidase deficiency?
Tracked treatments include Cerezyme, Cerdelga, Glustat, Zavesca.
What is the treatment for Glucosylceramide beta-glucosidase deficiency?
Standard treatment for Glucosylceramide beta-glucosidase deficiency includes Cerezyme, Cerdelga, Glustat, Zavesca. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Glucosylceramide beta-glucosidase deficiency patent cliff · Glucosylceramide beta-glucosidase deficiency CI report
- Treatment: Cerezyme · Sanofi
- Treatment: Cerdelga · Sanofi
- Treatment: Glustat
- Treatment: Zavesca · AstraZeneca
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing